Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind study of garsorasib versus docetaxel in previously treated KRAS G12C-mutant advanced or metastatic non-small cell lung cancer
CTR20240098Phase 3Active
- Sponsor
- InventisBio
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of garsorasib in non-small cell lung cancer (NSCLC), sponsored by InventisBio. Started Apr 2024; status: active.
02
Drugs
garsorasib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20240098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240098.